SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin reports Profit after tax of Rs 3163.60 Mln, in the March 2021 quarter

13 May 2021 Evaluate
The total revenue for the quarter ended March 2021 remained nearly unchanged at Rs. 25159.60 millions.A good growth in profit of 40.42% reported to Rs. 3163.60  millions over Rs. 2252.90 millions of corresponding previous quarter.The company reported a good operating profit of 4911.20 millions compared to 4453.20 millions of corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202103 202003 % Var 202103 202003 % Var 202103 202003 % Var
Sales 25159.60 24838.80 1.29 110559.30 110256.60 0.27 110559.30 110256.60 0.27
Other Income 660.70 2099.10 -68.52 1290.90 4751.90 -72.83 1290.90 4751.90 -72.83
PBIDT 4911.20 4453.20 10.28 21731.50 23828.00 -8.80 21731.50 23828.00 -8.80
Interest 123.10 113.80 8.17 406.20 525.90 -22.76 406.20 525.90 -22.76
PBDT 4788.10 4339.40 10.34 21325.30 15710.00 35.74 21325.30 15710.00 35.74
Depreciation 1250.10 1247.80 0.18 5028.30 5187.50 -3.07 5028.30 5187.50 -3.07
PBT 3538.00 3091.60 14.44 16297.00 10522.50 54.88 16297.00 10522.50 54.88
TAX 374.40 838.70 -55.36 3710.80 3247.00 14.28 3710.80 3247.00 14.28
Deferred Tax 236.70 -263.20 -189.93 82.30 -373.50 -122.03 82.30 -373.50 -122.03
PAT 3163.60 2252.90 40.42 12586.20 7275.50 72.99 12586.20 7275.50 72.99
Equity 907.40 906.00 0.15 907.40 906.00 0.15 907.40 906.00 0.15
PBIDTM(%) 19.52 17.93 8.88 19.66 21.61 -9.05 19.66 21.61 -9.05

Lupin Share Price

2476.10 77.40 (3.23%)
03-Jul-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1904.65
Dr. Reddys Labs. 1374.55
Cipla 1458.45
Zydus Lifesciences 1141.00
Lupin 2476.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: